In 2008, we entered into a contract with the Naval Medical Research Center (NMRC) to manufacture a dengue DNA vaccine formulated with our Vaxfectin® adjuvant. We manufactured the vaccine and the adjuvant under a $1.3 million contract, and provided regulatory and clinical expertise. The NMRC has completed a Phase 1 clinical trial using the vaccine. While we do not have any ongoing rights to the NMRC’s dengue DNA vaccine, the vaccine does incorporate our patented Vaxfectin®. Therefore any commercialization of the vaccine would require a license to these patents.
According to the World Health Organization, up to 2.5 billion people across the world are at risk for dengue infections. Dengue hemorrhagic fever and dengue shock syndrome are two serious forms of dengue infection. Dengue virus infects up to 100 million and results in over 500,000 hospitalizations and 12,500 deaths each year. There are four serotypes of dengue virus, all spread by mosquitoes. An individual infected by one serotype of dengue virus develops lifelong immunity against that serotype, but not against other serotypes. Because of this the NMRC is developing a tetravalent vaccine to cover all 4 serotypes.